BACKGROUND Novel immune therapies targeting tumor specific antigens are being developed. Our purpose was to determine expression of the cancer testes antigen NY-ESO-1 in renal cell carcinoma (RCC), as NY-ESO-1 targeting approaches, particularly adoptive cell therapy, have not been evaluated in this disease. METHODS We employed tissue microarrays containing >300 unique RCC cases and adjacent b...

In previous studies, the shared cancer-testis Ag, NY-ESO-1, was demonstrated to be recognized by both Abs and CD8+ T cells. Gene expression of NY-ESO-1 was detected in many tumor types, including melanoma, breast, and lung cancers, but was not found in normal tissues, with the exception of testis. In this study, we describe the identification of MHC class II-restricted T cell epitopes from NY-E...

Epoxidized soybean oil (ESO) was successfully thermal-cured by using methylhexahydrophthalic anhydride (MHHPA) curing agent, in the presence of tetraethylammonium bromide (TEAB) catalyst of varied concentration (0.3–0.8 phr). The polyesterification process of ESO thermoset was proven and supported by Fourier transforms infrared spectroscopy (FTIR) and gas chromatography-mass spectroscopy analys...

We show correlation between strong and decreased NY-ESO-1specific immunity with spontaneous regression and subsequent recurrence, respectively, in a long-surviving patient with an NY-ESO-1-expressing lung adenocarcinoma. An integrated immune response consisting of IgG antibody, as well as CD4 and CD8 T cells, against NY-ESO-1 was observed at the time of spontaneous regression of multiple pleura...

BACKGROUND NY-ESO-1 is a human gene that codes for antigens that are expressed in malignancies of various histological types, but not in normal tissues, except the testes. The expression of NY-ESO-1 in intracranial brain tumors including astrocytomas (ASTRs) and medulloblastomas (MEDs)/primitive neuroectodermal tumors (PNETs) was examined since the expression of NY-ESO-1 has only previously bee...

Immunization of cancer patients with vaccines containing full-length tumor Ags aims to elicit specific Abs and both CD4(+) and CD8(+) T cells. Vaccination with protein Ags, however, often elicits only CD4(+) T cell responses without inducing Ag-specific CD8(+) T cells, as exogenous protein is primarily presented to CD4(+) T cells. Recent data revealed that Ab-mediated targeting of protein Ags t...

he European Stroke Organisation (ESO) has entered its 8th year since formation from the politically active European Stroke Council and educational European Stroke Initiative. It has grown into a vibrant society of professionals with multiple strands to its activities. Members and fellows of ESO help in its mission to improve and harmonize stroke treatment in Europe through research and educatio...

The hypomethylating agent decitabine induces expression of the cancer/testis antigen NY-ESO-1 in the myeloid cells of patients with myelodysplastic syndrome (MDS). Patients with MDS treated with decitabine and an NY-ESO-1 vaccine developed NY-ESO-1-specific T-cell responses directed against their abnormal myeloid cells, raising hopes for combinatorial immunotherapy of this disease. Clin Cancer ...